Related references
Note: Only part of the references are listed.RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives
Alfredo Addeo et al.
PHARMACOLOGY & THERAPEUTICS (2023)
Integrated analysis of transcription factor-mRNA-miRNA regulatory network related to immune characteristics in medullary thyroid carcinoma
Danfeng Weng et al.
FRONTIERS IN IMMUNOLOGY (2023)
Medullary thyroid cancer with RET V804M mutation: more indolent than expected?
Nicholas A. Frisco et al.
SURGERY (2023)
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading
C. Christofer Juhlin et al.
ENDOCRINE-RELATED CANCER (2023)
Molecular targets of tyrosine kinase inhibitors in thyroid cancer
Poupak Fallahi et al.
SEMINARS IN CANCER BIOLOGY (2022)
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian et al.
THYROID (2022)
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer The REALITY Randomized Clinical Trial
Yansong Lin et al.
JAMA ONCOLOGY (2022)
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
S. Filetti et al.
ANNALS OF ONCOLOGY (2022)
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
Maria San Roman-Gil et al.
CANCER TREATMENT REVIEWS (2022)
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Steven G. Waguespack et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
Ezra Y. Rosen et al.
NATURE COMMUNICATIONS (2022)
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
Elizabeth S. Duke et al.
CLINICAL CANCER RESEARCH (2022)
Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review
Jiayi Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis
Youwen Zhu et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)
Takuya Higashiyama et al.
EUROPEAN JOURNAL OF CANCER (2022)
Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives
Katerina Saltiki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)
Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
Alice Nervo et al.
CANCER MANAGEMENT AND RESEARCH (2022)
RET kinase inhibitors for RET-altered thyroid cancers
Danica M. Vodopivec et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
Yan-Song Lin et al.
THYROID (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Non-coding RNA in thyroid cancer - Functions and mechanisms
Jun Cao et al.
CANCER LETTERS (2021)
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Christelle de la Fouchardiere et al.
EUROPEAN JOURNAL OF CANCER (2021)
Current practice in patients with differentiated thyroid cancer
Martin Schlumberger et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Multikinase inhibitors in thyroid cancer: timing of targeted therapy
Matti L. Gild et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Christine Dierks et al.
THYROID (2021)
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Dapeng Li et al.
CLINICAL CANCER RESEARCH (2021)
DNA Methylation Age Drift Is Associated with Poor Outcomes and De-Differentiation in Papillary and Follicular Thyroid Carcinomas
Tiantian Liu et al.
CANCERS (2021)
Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer
Yan-Song Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Lori J. Wirth et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Endocrine toxicities of immune checkpoint inhibitors
Jordan J. Wright et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Sergio Di Molfetta et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Xiangqian Zheng et al.
CLINICAL CANCER RESEARCH (2021)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2021)
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Vivek Subbiah et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS
Ji Min Oh et al.
THERANOSTICS (2021)
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
Nigel Fleeman et al.
HEALTH TECHNOLOGY ASSESSMENT (2020)
The Year in Medical Thyroidology Review: Current Challenges and Future Directions
Naifa Lamki Busaidy
THYROID (2020)
Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
Jiaying Chen et al.
THYROID (2020)
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019
Anastasios Maniakas et al.
JAMA ONCOLOGY (2020)
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A. Dunn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Janice M. Mehnert et al.
BMC CANCER (2019)
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model
Paul Tappenden et al.
HEALTH TECHNOLOGY ASSESSMENT (2019)
Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects
Tihana Ibrahimpasic et al.
THYROID (2019)
DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions
Mateus Camargo Barros-Filho et al.
THYROID (2019)
Leukocyte Mitochondrial DNA Copy Number and Risk of Thyroid Cancer: A Two-Stage Case-Control Study
Jian Zheng et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Maria E. Cabanillas et al.
ENDOCRINE REVIEWS (2019)
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Filetti et al.
ANNALS OF ONCOLOGY (2019)
A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
Shunji Takahashi et al.
FUTURE ONCOLOGY (2019)
Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
Viswanath Gunda et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing
Raffaele Ciampi et al.
ISCIENCE (2019)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao et al.
MOLECULAR CANCER (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Priyanka C. Iyer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications
Douglas Van Nostrand
THYROID (2018)
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
Viswanath Gunda et al.
BRITISH JOURNAL OF CANCER (2018)
The safety of apatinib for the treatment of gastric cancer
Ruixuan Geng et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Therapeutic advances in anaplastic thyroid cancer: a current perspective
Shikha Saini et al.
MOLECULAR CANCER (2018)
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenvatinib for Anaplastic Thyroid Cancer
Makoto Tahara et al.
FRONTIERS IN ONCOLOGY (2017)
TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer
M. Zou et al.
ONCOGENE (2016)
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
NON-CODING RNAs IN DEVELOPMENT AND DISEASE: BACKGROUND, MECHANISMS, AND THERAPEUTIC APPROACHES
Julia Beermann et al.
PHYSIOLOGICAL REVIEWS (2016)
Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer
Yanlan Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
RAS proto-oncogene in medullary thyroid carcinoma
Margarida M. Moura et al.
ENDOCRINE-RELATED CANCER (2015)
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Sun Min Lim et al.
EUROPEAN JOURNAL OF CANCER (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Thyroid Cancer
Tobias Carling et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) Enhancer (NDE) Is Associated With Reduced NIS Expression in Thyroid Tumors
Ana Luiza Galrao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
MUC1 Expression in Papillary Thyroid Carcinoma Is Associated with BRAF Mutation and Lymph Node Metastasis; the Latter is the Most Important Risk Factor of Relapse
Florence Renaud et al.
THYROID (2014)
Definition and management of radioactive iodine-refractory differentiated thyroid cancer
Martin Schlumberger et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
Panayiotis Savvides et al.
THYROID (2013)
Molecular pathogenesis and mechanisms of thyroid cancer
Mingzhao Xing
NATURE REVIEWS CANCER (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular genetics and diagnosis of thyroid cancer
Yuri E. Nikiforov et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Zhi Liu et al.
CLINICAL CANCER RESEARCH (2010)
Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma
Clarissa Capp et al.
THYROID (2010)
Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1
Julio C. Ricarte-Filho et al.
CANCER RESEARCH (2009)
Association of PTEN Gene Methylation With Genetic Alterations in the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway in Thyroid Tumors
Peng Hou et al.
CANCER (2008)
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Jia-Jing Lee et al.
ENDOCRINE-RELATED CANCER (2008)
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers
Zhi Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer
T. Kogai et al.
ENDOCRINE-RELATED CANCER (2006)
RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
MA Kouvaraki et al.
THYROID (2005)
Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors
T Dwight et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)